Clinical Trials Logo

Advanced Gastric Cancer clinical trials

View clinical trials related to Advanced Gastric Cancer.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06432075 Not yet recruiting - Clinical trials for Advanced Gastric Cancer

Neoantigen Reactive T Cells c for Chinese Patients With Advanced Gastric Cancer

Start date: June 1, 2024
Phase: Early Phase 1
Study type: Interventional

The purpose of this study is to see the safety and efficient of neoantigen reactive T cells (NRTs) in the treatment of Chinese patients with advanced gastric cancer.

NCT ID: NCT05649163 Not yet recruiting - Clinical trials for Advanced Solid Tumor

Real-world Study of HER2-overexpressed Advanced Solid Tumors After Progression of First-line Standard Therapy

Start date: January 2023
Phase:
Study type: Observational

The goal of this observational study is to learn about in describe treatment pattern and clinical outcomes in patients with HER2-overexpressed advanced solid tumors after progression of first-line standard therapy. The main questions it aims to answer are: - To evaluate the real-world safety and efficacy of Disitamab Vedotin in second-line and beyond treatment of advanced solid tumors with HER2 overexpression - To describe the treatment pattern and clinical outcomes of patients with advanced gastric cancer with HER2 overexpression in real world Settings after the failure of first-line standard therapy.

NCT ID: NCT04286711 Not yet recruiting - Clinical trials for Advanced Gastric Cancer

Clinical Study of Albumin-paclitaxel Combined With Apatinib and Camrelizumab in Advanced Gastric Cancer

Start date: March 2020
Phase: Phase 1/Phase 2
Study type: Interventional

This study is to evaluate the tolerance of albumin paclitaxel combined with apatinib and Camrelizumab in the second-line treatment of advanced gastric cancer to determine the maximum tolerable dose (MTD) of the combination.

NCT ID: NCT03954756 Not yet recruiting - Clinical trials for Advanced Gastric Cancer

Exploratory Clinical Study of Apatinib and PD-1 in Treating Advanced Gastric Cancer

Start date: June 1, 2019
Phase: Phase 2
Study type: Interventional

The Purpose of This Study is to Evaluate the Efficacy and Safety of Apafitini Combined With PD1 in Patients With Advanced Gastric Cancer After Second-line Treatment Failure, Thus Providing More Options for Patients With Advanced Gastric Cancer.

NCT ID: NCT03137004 Not yet recruiting - Clinical trials for Advanced Gastric Cancer

Docetaxel and S-1 Combination Therapy as Second-line Treatment for Advanced Gastric Cancer

Start date: June 1, 2017
Phase: Phase 2
Study type: Interventional

A single-arm phase II study to evaluate the efficacy and safety of docetaxel plus S-1 (DS) as second-line treatment in patients with AGC.

NCT ID: NCT02038621 Not yet recruiting - Clinical trials for Advanced Gastric Cancer

The Maintenance Therapy of Capecitabine of Advanced Gastric Cancer

GZH-001
Start date: January 2014
Phase: Phase 2
Study type: Interventional

To confirm the efficacy and safety of XELOX with capecitabine maintenance in treatment of advanced gastric cancer (AGC)

NCT ID: NCT01206218 Not yet recruiting - Clinical trials for Advanced Gastric Cancer

Evaluation of Customized Treatment According to BRCA1 Assessment in Patients With Advanced Gastric Cancer

BREC-AGC
Start date: October 2010
Phase: Phase 2/Phase 3
Study type: Interventional

Evaluation of customized treatment according to BRCA1 assessment in patients with advanced gastric cancer

NCT ID: NCT00845884 Not yet recruiting - Clinical trials for Advanced Gastric Cancer

Phase I/II Study of Weekly Docetaxel and Cisplatin Together With Capecitabine and Bevacizumab in Advanced Gastric Cancer

Start date: February 2009
Phase: Phase 1/Phase 2
Study type: Interventional

In spite of multiple attempts to improve the efficacy of first-line chemotherapy in advanced gastric cancer, the progress that has been achieved so far is rather limited, and many investigators are exploring newer regimens.A combination of decetaxel (Taxotere) with Cisplatin and 5-fluorouracil (5FU) is considered one of the most effective regimens in this disease. However, it is associated with significant toxicity which avoided its general adaptation by the medical community. The current study is exploring a newer way to administer these three drugs, hopefully making the regimen more comfortable, less toxic and maybe even more effective. We will do this by changing the dose and timing of Taxotere and Cisplating, by replacing protracted infusion of 5FU with tablets of Capecitabine (Xeloda) and by adding the anti-angiogenic drug, Bevacizumab (Avastin), which had shown encouraging results in this disease.